

# Starpharma Expands Lilly Partnership

**MELBOURNE; 30 September 2010:** Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.

The new agreement relates to a co-development program for one of Starpharma's dendrimer-drug conjugates. Under the agreement Lilly will receive an option on the conjugate, will pay research fees to Starpharma and will conduct studies in animal models to advance the compound. The identity of the conjugate cannot be disclosed at this time due to confidentiality restrictions.

This latest announcement follows on from two previous agreements between the companies. In February 2010, Starpharma announced that its dendrimer drug delivery technology will be applied to enhance compounds in Lilly's human pharmaceutical portfolio.

In May 2009 Starpharma and Lilly's animal health division, Elanco, signed an agreement to develop new animal health products with enhanced properties.

"We are delighted that Lilly has chosen to expand the scope of its partnership with us once again," said Dr Jackie Fairley, CEO Starpharma. "The agreement follows on from an initial evaluation in animal models of this conjugate by Lilly. Starpharma now looks forward to developing the compound as rapidly as possible with Lilly."

---

## About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners. For further information: [www.starpharma.com](http://www.starpharma.com)

## Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

## For further information:

Media - Buchan Consulting		Starpharma - <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b> Mob: +61 417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>	<b>Jessica Sealby</b> Tel: +61 3 9866 4722 <a href="mailto:jsealby@bcg.com.au">jsealby@bcg.com.au</a>	<b>Dr Jackie Fairley</b> Chief Executive Officer +61 3 8532 2704	<b>Nigel Baade</b> Chief Financial Officer +61 3 8532 2704 <a href="mailto:nigel.baade@starpharma.com">nigel.baade@starpharma.com</a>